VIEW Analysts, investors not surprised by Novo’s Alzheimer trial failure

view original post

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet their main goal, sending shares of the Danish drugmaker down around 9% to …